NCT02324842View on ClinicalTrials.gov

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 28, 2018

Study Completion Date

March 31, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Canagliflozin

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)

DRUG

Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Trial Locations (1)

78229

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02324842 - Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter